Substantia nigra related gene polymorphisms associated with antipsychotic-induced acute movement disorders: a genome-wide association study and multi-ancestry validation in schizophrenia

黑质相关基因多态性与抗精神病药物诱发的急性运动障碍相关:一项全基因组关联研究和精神分裂症多祖先验证

阅读:1

Abstract

BACKGROUND: Antipsychotic-induced movement disorders (AIMDs) are prevalent side effects of antipsychotics, particularly during the acute phase of treatment. This study aimed to elucidate the genetic mechanisms underlying AIMDs using a genome-wide association study (GWAS). METHODS: GWASs on AIMDs were conducted in 3 independent cohorts: a discovery cohort of 3067 patients (2016 subjects were reserved after quality control), a validation cohort of 277 patients, and a multi-ancestry validation cohort of 766 patients. Subsequent post-GWAS analyses included gene-based analyses, transcriptome-wide association studies (TWASs), and polygenic risk score (PRS) profiling. RESULTS: Our study identified 2 loci located in RAB44 gene (rs116249243, P = 5.98 × 10(-9); rs117097482, P = 1.17 × 10(-8)) associated with extrapyramidal symptoms (EPSs), 1 locus (rs6826172, P = 5.56 × 10(-9)) related to akathisia, and 76 loci linked to involuntary movements (11 genes were mapped). Risk loci located in CNTNAP2, LUZP2, TMEM167A, and RAB44 genes were successfully replicated in the validation cohort, whereas the locus located in RAB44 was also replicated in the multi-ancestry cohort. Gene-based analyses indicated that XRCC4 and PAIP2B reached significance at the genome-wide level in involuntary movements. Tissue expression analysis revealed that involuntary movement-related genes are predominantly expressed in the substantia nigra. Additionally, the TWAS suggested a causal relationship between XRCC4 and involuntary movement. The PRSs derived from the discovery cohort significantly predicted AIMDs in the validation cohort, with area under the receiver operating characteristic curve (AUC) values from 0.60 to 0.80. CONCLUSIONS: Our findings highlight the role of substantia nigra related gene polymorphisms in AIMDs. This study provides novel insights into the pathogenesis of AIMDs and supports the potential for personalized treatment approaches for schizophrenia. TRIAL REGISTRATION: ChiCTR ( https://www.chictr.org.cn/showproj.html?proj=8604 ), No. ChiCTR-TRC-10000934; ChiCTR ( https://www.chictr.org.cn/showproj.html?proj=129668 ), No. ChiCTR2100048320.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。